Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654752 · ClinicalTrials.gov registry record · NA
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
A NA study of Cystic Fibrosis, sponsored by University of Washington, the Collaborative Health Studies Coordinating Center.
- Recruiting
- Registry status
- NA
- Development phase
- 430
- Enrollment target
- 20
- Study locations
NCT06654752: Recruiting NA study of Cystic Fibrosis, sponsored by University of Washington, the Collaborative Health Studies Coordinating Center.
NCT06654752 is a NA study of Cystic Fibrosis that is actively recruiting participants, run by University of Washington, the Collaborative Health Studies Coordinating Center. The registered enrollment target is 430 participants, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (143% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06654752, a NA study of Cystic Fibrosis, is actively recruiting participants, sponsored by University of Washington, the Collaborative Health Studies Coordinating Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 430 participants
- Enrollment target
- 20
- Study locations
Study Summary
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Primary Outcome
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.
Conditions Studied
Interventions
- OTHER Immediate Oral Antibiotics
- OTHER Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Study Locations (20)
California
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic - Los Angeles
- Stanford University - Palo Alto
- Rady Children's Hospital at University of California San Diego - San Diego
Minnesota
- Children's Hospitals and Clinics of Minnesota - Minneapolis
- The Minnesota Cystic Fibrosis Center & University of Minnesota - Minneapolis
Missouri
- Children's Mercy Hospital - Kansas City
- St. Louis Children's Hospital & Washington University School of Medicine - St Louis
Alabama
- The Children's Hospital Alabama & University of Alabama at Birmingham - Birmingham
Arizona
- Tucson Cystic Fibrosis Center - Tucson
Colorado
- Children's Hospital of Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta & Emory University - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2024-12-01 |
| Est. Completion | 2029-02-28 |
| Phase | NA |
Sponsor
University of Washington, the Collaborative Health Studies Coordinating Center5 total trials
What NCT06654752 shows while recruiting
NCT06654752 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (143% higher).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Immediate Oral Antibiotics is the first listed.
NCT06654752 names 20 study sites across 16 states, led by California, Minnesota, Missouri.
Frequently Asked Questions
What is clinical trial NCT06654752 about?
NCT06654752 is a clinical study titled "Streamlined Treatment of Pulmonary Exacerbations in Pediatrics". The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
What is the current status of trial NCT06654752?
This trial is currently recruiting. It is a NA study. The enrollment target is 430 participants. The study started on 2024-12-01. Estimated completion is 2029-02-28.
What conditions does trial NCT06654752 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT06654752?
The interventions under investigation include: Immediate Oral Antibiotics (OTHER), Tailored Treatment: Oral Antibiotics only if Additional Treatment needed (OTHER).
Who is sponsoring clinical trial NCT06654752?
This trial is sponsored by University of Washington, the Collaborative Health Studies Coordinating Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06654752 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06654752's enrollment target sits among peer trials
430 15th of 169 higher than 155 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
FEED-Cystic Fibrosis (FEED-CF)
RECRUITING · NA
-
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
RECRUITING · NA
-
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
RECRUITING · NA
-
Lung Transplant READY CF 2: CARING CF Ancillary RCT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI